• info@thehrctest.co.uk
  • 020 8050 2578

Testing for Leukaemia

Transforming Leukaemia Screening with Proactive Diagnostics

Leukaemia is a complex blood cancer that can develop rapidly, often without clear early symptoms. In the UK, many cases are diagnosed only after significant disease progression, largely because early‑stage leukaemia is difficult to detect using conventional methods. Early diagnosis is critical for improving outcomes, yet traditional screening typically identifies leukaemia only once abnormal blood counts or symptoms appear. Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before abnormalities are visible in routine tests.

The HrC test represents a new generation of leukaemia screening—one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into leukaemia risk than conventional methods alone.

Current Methods for Diagnosing Leukaemia

Leukaemia diagnosis in the UK typically involves several established tools used within the NHS and private healthcare settings:

  • Full Blood Count (FBC): The most common initial test, used to identify abnormal levels of white blood cells, red blood cells, or platelets.
  • Peripheral Blood Smear: A microscopic examination of blood cells to detect abnormal or immature cells.
  • Bone Marrow Biopsy: A procedure used to confirm diagnosis and determine the specific type of leukaemia.
  • Flow Cytometry and Genetic Testing: Advanced laboratory tests used to classify leukaemia subtypes and guide treatment decisions.

These methods have been essential in improving outcomes, yet they remain reactive—they detect cancer only after visible changes occur.

Limitations of Conventional Leukaemia Screening

Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:

  • No Routine Screening: Unlike many solid‑tumour cancers, there is no national screening programme for leukaemia in the UK.
  • Subtle Early Signs: Early‑stage leukaemia may not cause noticeable symptoms or abnormal blood counts, making it difficult to detect.
  • Rapid Progression: Some forms of leukaemia can progress quickly, reducing the window for early intervention.
  • Invasive Diagnostics: Bone marrow biopsies can be uncomfortable and carry risks such as bleeding and infection.
  • False Reassurance: Normal blood tests do not always rule out early leukaemia, as molecular changes often occur long before blood counts shift.

These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms or blood abnormalities appear.

The HrC Test: A Breakthrough in Early Leukaemia Detection

The HrC test introduces a transformative approach to leukaemia screening by focusing on the earliest biological drivers of cancer. Instead of waiting for abnormal blood counts or symptoms, the test isolates and analyses Cancer Stem Cells (CSCs)—the rare cells responsible for initiating cancer development.

A simple 12ml blood sample enables the HrC test to deliver:

  • A 12–18 Month Early Warning Window: Detection of cancer‑initiating molecular activity long before conventional blood tests or biopsies can identify abnormalities.
  • High Sensitivity and Clear Results: With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
  • Reliable “Safe Zone” Assessment: A clear indication of “no risk” offers reassurance that leukaemia is not present and is unlikely to develop within the next year.

This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.

Comprehensive Cancer Screening Through a Single Test

Pan‑Cancer Detection for Complete Health Protection

Although this document focuses on leukaemia, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.

Key Advantages Include:

  • Holistic Health Monitoring: Simultaneous assessment of leukaemia risk alongside other major cancers such as Bladder, Bowel, Breast, Cervical, Kidney, Liver, Lung, Lymphoma, Ovarian, Pancreatic and Prostate.
  • Actionable Insights: Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies.
  • One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.

Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.

About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here